User: Guest

ACUTE MYELOID LEUKEMIA (AML) THERAPEUTICS

Global Market Trajectory & Analytics

MCP-6847

VALIDATED EXECUTIVE ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

5362

Interactions with Platform & by Email *

INTERACTIONS

858

Unique # Participated *

PARTICIPANTS

161

Responses Validated *

VALIDATIONS

72

* Login to view program details and full enterprise executive list.

  •  DATE

    JUNE 2020

  •  TABLES

    123

  •  PAGES

    187

  •  EDITION

    16

  •  PRICE

    US$5450

COVID-19 IMPACT SURVEY MAY 2020
Amid the COVID-19 crisis and the looming economic recession, the Acute Myeloid Leukemia (AML) Therapeutics market worldwide will grow by a projected US$1 Billion, during the analysis period, driven by a revised compounded annual growth rate (CAGR) of 12.9%. Cytarabine, one of the segments analyzed and sized in this study, is forecast to grow at over 16.7% and reach a market size of US$698.7 Million by the end of the analysis period. An unusual period in history, the coronavirus pandemic has unleashed a series of unprecedented events affecting every industry. The Cytarabine market will be reset to a new normal which going forwards in a post COVID-19 era will be continuously redefined and redesigned. Staying on top of trends and accurate analysis is paramount now more than ever to manage uncertainty, change and continuously adapt to new and evolving market conditions.

As part of the new emerging geographic scenario, the United States is forecast to readjust to a 10.8% CAGR. Within Europe, the region worst hit by the pandemic, Germany will add over US$38.4 Million to the region's size over the next 7 to 8 years. In addition, over US$31.5 Million worth of projected demand in the region will come from Rest of European markets. In Japan, the Cytarabine segment will reach a market size of US$20 Million by the close of the analysis period. Blamed for the pandemic, significant political and economic challenges confront China. Amid the growing push for decoupling and economic distancing, the changing relationship between China and the rest of the world will influence competition and opportunities in the Acute Myeloid Leukemia (AML) Therapeutics market. Against this backdrop and the changing geopolitical, business and consumer sentiments, the world's second largest economy will grow at 18.1% over the next couple of years and add approximately US$213.3 Million in terms of addressable market opportunity. Continuous monitoring for emerging signs of a possible new world order post-COVID-19 crisis is a must for aspiring businesses and their astute leaders seeking to find success in the now changing Acute Myeloid Leukemia (AML) Therapeutics market landscape. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.

Competitors identified in this market include, among others, AbbVie Inc.; Agios Pharmaceuticals, Inc.; Amgen Inc.; Astellas Pharma Inc.; Astex Pharmaceuticals, Inc.; Celgene Corporation; CTI BioPharma Corp.; Cyclacel Pharmaceuticals, Inc.; Daiichi Sankyo Company Limited; F. Hoffmann-La Roche AG; Immune Pharmaceuticals Inc.; Janssen-Cilag Limited; Jazz Pharmaceuticals plc; MEI Pharma, Inc.; Novartis AG; Pfizer Inc.; Seattle Genetics, Inc.; Stemline Therapeutics, Inc.; Sunesis Pharmaceuticals, Inc.; Tolero Pharmaceuticals, Inc.

SEGMENTS

» Chemotherapy Type (Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites, Other Chemotherapy Types)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » Spain » Russia » and Rest of Europe » Asia-Pacific » Australia » India » South Korea » and Rest of Asia-Pacific » Latin America » Argentina » Brazil » Mexico » and Rest of Latin America » Middle East » Iran » Israel » Saudi Arabia » United Arab Emirates » and Rest of Middle East » and Africa
   PURCHASE REPORT        $5450.00
VIEW FULL REPORT INDEX PROJECT COMPENDIUM * EXPERT PANEL

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com